The FY2023 (Dec) proxy of Rocket Pharmaceuticals names 16 peer companies for pay. Among Rocket Pharmaceuticals and these peers, CEO pay was the highest of 4 and total shareholder return was 2nd highest of 4.
1st highest of 4in Rocket Pharmaceuticals and its pay peers, FY2023 (Dec) by CEO pay:
$3.6M$8.0M
2nd highest of 4in Rocket Pharmaceuticals and its pay peers, FY2023 (Dec) by total shareholder return:
$44$145
Pay peer group, FY2023 (Dec) proxy
| Beam Therapeutics | ||
| Regenxbio | ||
| Replimune Group | ||
| Agios | Not disclosed | Not disclosed |
| Allogene | Not disclosed | Not disclosed |
| Amicus | Not disclosed | Not disclosed |
| Bluebird bio | Not disclosed | Not disclosed |
| BridgeBio | Not disclosed | Not disclosed |
| CRISPR AG | Not disclosed | Not disclosed |
| Editas | Not disclosed | Not disclosed |
| Intellia | Not disclosed | Not disclosed |
| Krystal | Not disclosed | Not disclosed |
| Mirati | Not disclosed | Not disclosed |
| Rhythm | Not disclosed | Not disclosed |
| Tenaya | Not disclosed | Not disclosed |
| Ultragenyx | Not disclosed | Not disclosed |
16 companies
Changes by year
FY2024 (Dec) proxy
- RemovediQure N.V.pay peer group
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.